event-trade登录编辑
RTTNews BiotechDoubao · 实盘不做把握 7/10不做原因:标的无直接敞口
北京时间·🕒 发布 22:50:24·⟳ 抓取 23:00:17 +9m53s·⚡ 决策 10-08 23:04:16 +3m59s·18.8 天前

Myriad Genetics、SOPHiA GENETICS 与阿斯利康合作开发前列腺癌基因组不稳定性评分 PrGIS

这是一项处于研究/临床试验阶段的伴随诊断合作,未披露任何金额、里程碑或商业化条款,PrGIS 尚未获批、不产生收入,对三家公司均无可量化的短期业绩影响;盘面反应(MYGN -3.39%、SOPH +0.70%、AZN +1.47%)也确认市场未将其视为实质利好,无正期望交易机会。

📄 原文RTTNews Biotech↗ 原文
Myriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 Myriad Genetics(MYGN.US)
无金额的早期研发合作,PrGIS 尚处临床试验阶段、无收入贡献,且消息当日股价下跌 3.39%,无可交易 edge
不做 SOPHiA GENETICS(SOPH.US)
仅平台整合层面的早期合作,无订单或里程碑金额,当日微涨 0.70% 不构成事件驱动机会
不做 AstraZeneca(AZN.US)
诊断端早期研究合作相对阿斯利康市值可忽略,不构成个股催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

Myriad 与 SOPHiA 联手阿斯利康推进前列腺癌 HRD 评分 PrGIS,但本质是无金额的早期研发合作、尚处临床试验阶段,对任何一方短期收入均无实质影响,消息当日股价也未同向重定价,故回避。

🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗

关键理由

  • 合作处于 PrGIS 生物标志物验证和临床试验阶段,无美元金额、无获批产品、无收入,无法建立 materiality。
  • 市场即时反应平淡甚至负面(MYGN 当日 -3.39%),不存在新鲜事件驱动的价格 edge。

主要风险

  • 若 ESMO 2026 公布的 PrGIS 数据显著优于预期并后续获里程碑付款,可能重估,但那是新事件而非当前催化。

反向证据

  • 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
    现有报道无任何财务条款,MYGN 当日反跌 3.39%,且其最近季度收入同比下滑 11%,无正催化支撑
    检索:Myriad Genetics SOPHiA PrGIS deal terms revenue milestone payment 原文 ↗

先例如何影响了这次决策

对本次决策的影响:先例缺失未改变结论:事件处于无收入的研究阶段,历史涨幅均不能创造当前 edge

方向:无可引用的对齐先例;但早期无金额研发合作缺乏可交易催化这一判断不依赖先例涨幅

涨幅量级:无高相似先例校准幅度,且因事件无 materiality,无需校准

形态:未见可用的见光死样本;盘面本身已显示无利好反应

工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
  1. search_processed_events 成功 stock_tools HTTP · 12 ms
    {"result": "search_processed_events:agent query=`myriad genetics sophia genetics astrazeneca prgis prostate cancer collaboration | myriad mychoice cdx prgis homologous recombination deficiency prostate companion diagnostic | soph`;结构化索引覆盖完整 72 小时;旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整),返回 0 条候选。未命中只表示这些 agen

原文全文

展开原文 · 9,542 字
Myriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Myriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS
By
RTTNews Staff Writer
✉
Published:
10/8/2026 10:50 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Myriad Genetics (
MYGN
) and SOPHiA GENETICS (
SOPH
) announced a collaboration with AstraZeneca (
AZN
) to advance a new prostate cancer-specific genomic instability score, or PrGIS, for precision oncology.
Prostate cancer is an area where homologous recombination deficiency (HRD) is emerging as an important biomarker for identifying patients who may benefit from targeted treatments. PrGIS is designed to assess chromosomal instability associated with HRD in prostate cancer.
Myriad developed PrGIS to support the use of HRD as an actionable biomarker in prostate cancer. The company's MyChoice CDx test, currently used as a companion diagnostic in ovarian cancer, will generate the PrGIS score and is being advanced for use in prostate cancer.
The collaboration is intended to advance PrGIS in clinical trials and support the development of potential companion diagnostic solutions that could help identify appropriate patients for precision oncology medicines.
As part of the agreement, SOPHiA GENETICS is developing a decentralized companion diagnostic solution based on its Extended Homologous Recombination Solution for solid tumors. The solution will incorporate Myriad's PrGIS
technology
and is intended to expand access to testing in global
markets
.
SOPHiA GENETICS' cloud-based platform supports local laboratory testing through a network of more than 1,000 connected institutions across over 75 countries.
Myriad and AstraZeneca also plan to present research on PrGIS at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. The research is expected to further characterize the biomarker and support its validation.
The collaboration combines Myriad's genomic biomarker technology with SOPHiA GENETICS' global diagnostic platform, with the companies seeking to expand access to precision oncology testing and support development of companion diagnostics in prostate cancer.
MYGN has traded between $2.74 and $8.59 over the past year. Currently, MYGN is trading at $4.13, down 3.39%.
SOPH has traded between $3.75 and $8.98 over the past year. Currently, SOPH is trading at $7.20, up 0.70%.
AZN has traded between $153.41 and $212.71 over the past year. Currently, AZN is trading at $157.63, up 1.47%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
U.S. Stocks May Move Back To The Upside In Early Trading
September 29, 2026 08:54 ET
U.S. Stocks Under Pressure As Crude Oil Prices, Treasury Yields Surge
September 28, 2026 11:06 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Myriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS
Myriad Genetics Names Sikri Commercial EVP; Reaffirms 2026 Guidance
Myriad Genetics Q2 Loss Narrows; Revenue Falls 11%
Myriad Debuts FirstGene Four-in-One Prenatal Genetic Screening From Single Blood Sample
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
No Evidence Siberia Lab Worker Died Of Plague, Russia Tells WHO
October 08, 2026 10:10 ET
Canadian Author Anne Carson Wins Nobel Prize In Literature
October 08, 2026 09:42 ET
U.S. Jobless Claims Unexpectedly Dip From Upwardly Revised Level
October 08, 2026 09:16 ET
Nearly 70 Million Children Now Have A Trump Account: White House
October 08, 2026 08:27 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
ISIS-inspired Teenager Who Plotted Mass-Shooting At Mall Of America Arrested
October 08, 2026 07:39 ET
British Consulate In East Jerusalem Not Closing, But Renamed As UK Mission
October 08, 2026 07:21 ET
Istanbul Overtakes London Heathrow As World's Most-connected Airport
October 08, 2026 07:00 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Fed Minutes Reveal Officials Expect Another Rate Hike This Year
October 07, 2026 14:23 ET
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
October 07, 2026 12:14 ET
No Dangerous Infectious Disease Detected Among Russia Lab Worker Contacts: WHO
October 07, 2026 08:48 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Advanced Drainage Systems To Acquire StormTrap For $530 Mln
October 05, 2026 07:08 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

  1. 7c75f7c53f · 2026-10-08 23:04 · doubao / doubao-seed-evolving-latest-version · 策略包 0c89ec5cee9e当前